• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Panolos Bioscience, Inc.

Monday, June 03, 2024
CP
Multiple Therapeutics
Panolos Bioscience is a frontrunner in structural biology-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapeutics targeting cancer, autoimmune, and rare diseases. Panolos Bioscience's alpha-ART platform is a groundbreaking approach that fuses VEGFR1(D2D3) to Fc, creating a platform for attaching effector moieties to develop mono- or multi-specific therapeutics aimed at improving anti-cancer immunity and vascular normalization. This technology is pivotal in addressing the challenges faced in treating complex diseases like cancer, autoimmune, and metabolic disorders, which include unclear disease mechanisms and the difficulties of combining therapies for better patient outcomes.
Panolos Bioscience, Inc.
Company Website: http://www.panolos.com
Lead Product in Development: PB101
Number Of Unlicensed Products (For Which You Are Seeking Partners): Three

Company HQ City

Hwaseong-si

Company HQ State

Gyeonggi-do

Company HQ Country

Korea, Republic of

CEO/Top Company Official

Dr. Hyeseong (Edmond) Lim

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS